Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.68 CHF | +0.18% | -1.43% | -2.92% |
Feb. 16 | BB Biotech's Loss Narrows in FY23; Operating Income Down | MT |
Feb. 14 | BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.92% | 2.51B | C | ||
+3.13% | 43.43B | B | ||
+47.30% | 41.69B | A | ||
+8.49% | 41.31B | B- | ||
-10.82% | 27.14B | C | ||
+8.26% | 25.28B | B- | ||
-23.69% | 18.47B | B | ||
+1.58% | 12.33B | C+ | ||
+32.83% | 12.59B | C+ | ||
+6.63% | 11.03B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BION Stock
- Ratings BB Biotech AG